Literature DB >> 8450034

Intrinsic radiation resistance of primary clonogenic blasts from children with newly diagnosed B-cell precursor acute lymphoblastic leukemia.

F M Uckun1, W Jaszcz, M Chandan-Langlie, K G Waddick, K Gajl-Peczalska, C W Song.   

Abstract

The radiation sensitivity of primary clonogenic blasts from 44 children with newly diagnosed B-cell precursor acute lymphoblastic leukemia (ALL) was analyzed using leukemic progenitor cell (LPC) colony assays. The derived values for SF2 (surviving fraction at 200 cGy) and alpha (initial slope of radiation survival curves constructed according to the linear quadratic model) indicated a marked interpatient heterogeneity in intrinsic radiation sensitivity of LPC populations. The SF2 values ranged from 0.01 to 1.00 (median = 0.430; mean +/- SE = 0.47 +/- 0.04), and the alpha values ranged from 0.000 to 3.272 Gy-1 (median = 0.280 Gy-1; mean +/- SE = 0.430 +/- 0.093 Gy-1). When CD19+ CD34+ versus CD19+ CD34- immunophenotypes were compared, a trend toward higher SF2 and lower alpha values were observed in LPC from CD34+ patients, consistent with greater radiation resistance. When patients were divided into three approximately equal groups based on increasing levels of CD34 expression, a clear ordering effect was observed indicating that increased CD34 expression levels are associated with significantly higher radiation resistance at the level of B-lineage LPC. The highest CD34 expression group (> or = 75% positivity) had 1.4-fold higher SF2 (P = 0.05) and twofold lower alpha values (P = 0.06) than the lowest group (< 30% positivity). Furthermore, the CD34 positivity of radiation resistant (alpha < or = 0.2 and SF2 > or = 0.5) B-cell precursor ALL cases was greater than the CD34 positivity of radiation sensitive (alpha > 0.2 and/or SF2 < 0.5) cases (56 +/- 9% versus 34 +/- 9%, P = 0.09). Whereas only 6 of 16 (38%) of radiation sensitive cases were CD34+, 11 of 15 (73%) of radiation resistant cases expressed CD34 (P = 0.04). Our results offer new insights into the inherent and/or acquired radiation resistance of primary clonogenic blasts from B-cell precursor ALL patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8450034      PMCID: PMC288058          DOI: 10.1172/JCI116261

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  61 in total

1.  Cell kinetics of irradiated experimental tumors: relationship between the proliferating and the nonproliferating pool.

Authors:  M Potmesil; D Ludwig; A Goldfeder
Journal:  Cell Tissue Kinet       Date:  1975-07

2.  Repair of sub-lethal and potentially lethal radiation damage in plateau phase cultures of human cells.

Authors:  J B Little
Journal:  Nature       Date:  1969-11-22       Impact factor: 49.962

Review 3.  Allogenic bone marrow transplantation: current status and future directions.

Authors:  R J O'Reilly
Journal:  Blood       Date:  1983-11       Impact factor: 22.113

Review 4.  Bone marrow transplantation in acute leukemia.

Authors:  G W Santos; H Kaizer
Journal:  Semin Hematol       Date:  1982-07       Impact factor: 3.851

5.  Cyclic responses of cultured 9L cells to radiation.

Authors:  B F Kimler; S D Henderson
Journal:  Radiat Res       Date:  1982-07       Impact factor: 2.841

6.  Radiobiological basis of total body irradiation with different dose rate and fractionation: repair capacity of hemopoietic cells.

Authors:  C W Song; T H Kim; F M Khan; J H Kersey; S H Levitt
Journal:  Int J Radiat Oncol Biol Phys       Date:  1981-12       Impact factor: 7.038

7.  In vitro radiosensitivity of human leukemia cell lines.

Authors:  R R Weichselbaum; J S Greenberger; A Schmidt; A Karpas; W C Moloney; J B Little
Journal:  Radiology       Date:  1981-05       Impact factor: 11.105

8.  Inherent cellular radiosensitivity as a basic concept for human tumor radiotherapy.

Authors:  B Fertil; E P Malaise
Journal:  Int J Radiat Oncol Biol Phys       Date:  1981-05       Impact factor: 7.038

9.  Cell kinetics of irradiated experimental tumors: cell transition from the non-proliferating to the proliferating pool.

Authors:  M Potmesil; A Goldfeder
Journal:  Cell Tissue Kinet       Date:  1980-09

10.  Autologous bone marrow transplantation in high-risk remission B-lineage acute lymphoblastic leukemia using a cocktail of three monoclonal antibodies (BA-1/CD24, BA-2/CD9, and BA-3/CD10) plus complement and 4-hydroperoxycyclophosphamide for ex vivo bone marrow purging.

Authors:  F M Uckun; J H Kersey; R Haake; D Weisdorf; N K Ramsay
Journal:  Blood       Date:  1992-02-15       Impact factor: 22.113

View more
  4 in total

1.  STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress.

Authors:  Fatih M Uckun; Sanjive Qazi; Hong Ma; Lisa Tuel-Ahlgren; Zahide Ozer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-29       Impact factor: 11.205

2.  Low Dose Total Body Irradiation Combined With Recombinant CD19-Ligand × Soluble TRAIL Fusion Protein is Highly Effective Against Radiation-Resistant B-Precursor Acute Lymphoblastic Leukemia in Mice.

Authors:  Fatih M Uckun; Dorothea E Myers; Hong Ma; Rebecca Rose; Sanjive Qazi
Journal:  EBioMedicine       Date:  2015-04       Impact factor: 8.143

3.  Novel Bruton's tyrosine kinase inhibitors currently in development.

Authors:  Osmond J D'Cruz; Fatih M Uckun
Journal:  Onco Targets Ther       Date:  2013-03-06       Impact factor: 4.147

4.  Molecular features unique to glioblastoma radiation resistant residual cells may affect patient outcome - a short report.

Authors:  Ekjot Kaur; Jayant S Goda; Atanu Ghorai; Sameer Salunkhe; Prakash Shetty; Aliasgar V Moiyadi; Epari Sridhar; Abhishek Mahajan; Rakesh Jalali; Shilpee Dutt
Journal:  Cell Oncol (Dordr)       Date:  2018-10-26       Impact factor: 7.051

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.